Virax Biolabs Group Limited is a biotechnology company focused on the detection of immune responses to and diagnosis of viral diseases. The Company is engaged in developing ViraxImmune with the intention of providing an immunology profiling platform that assesses each individualâs immune risk profile against global viral diseases as well as helping with the early diagnosis of post-viral syndromes associated with T cell exhaustion and chronic inflammation. Its product portfolio includes ViraxClear and ViraxVet. ViraxClear offers a range of accurate diagnostic testing kits and machines. ViraxVet offers various rapid and molecular tests for small animal veterinary diagnostics. The Company is initially focused on diseases associated with post-viral syndromes, including SARS-CoV-2, Human Papillomavirus (HPV), Malaria, Hepatitis B, and Herpes (HSV-1).
äŒæ¥ã³ãŒãVRAX
äŒç€ŸåVirax Biolabs Group Ltd
äžå Žæ¥Jul 14, 2022
æé«çµå¶è²¬ä»»è
ãCEOãFoster (James)
åŸæ¥å¡æ°19
蚌åžçš®é¡Ordinary Share
æ±ºç®ææ«Jul 14
æ¬ç€Ÿæåšå°Biocity Glasgow
éœåžLONDON
蚌åžååŒæNASDAQ OMX - NASDAQ BASIC
åœUnited Kingdom
éµäŸ¿çªå·ML1 5UH
é»è©±çªå·4402077887414
ãŠã§ããµã€ãhttps://www.viraxbiolabs.com
äŒæ¥ã³ãŒãVRAX
äžå Žæ¥Jul 14, 2022
æé«çµå¶è²¬ä»»è
ãCEOãFoster (James)